|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Tumor-associated inflammatory microenvironment in non-small cell lung cancer: correlation with FGFR1 and TLR4 expression via PI3K/Akt pathway.
|
30854106 |
2019 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
The 8p11 myeloproliferative syndrome is an aggressive neoplasm associated with chromosomal abnormalities involving rearrangement of the fibroblast growth factor receptor 1 (FGFR1) gene.
|
25037443 |
2014 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
In conclusion, FGFR1 expression in TNBCs is independently prognostic of OS, and H-score of 100 or more FGFR1 immunostaining may define tumors that have treatment potential via FGFR signaling inhibition.
|
25868865 |
2015 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
In estrogen-free conditions, FGFR1 associated with ERα in tumor cell nuclei and regulated the transcription of ER-dependent genes.
|
28751448 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
MicroRNA-133b (miR-133b), through directly targeting the fibroblast growth factor receptor 1 (FGFR1), is increasingly recognized as a tumor suppressor in different types of cancers.
|
30574019 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
To determine whether bFGF and FGFR-1 are also required for tumor formation in these cells, liposome-mediated gene transfer was used to deliver episomal vectors containing antisense-oriented bFGF or FGFR-1 cDNAs into human melanomas, grown as subcutaneous tumors in nude mice.
|
9256280 |
1997 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Microscopic analysis of the xenograft tumors revealed a reduced Ki-67 labeling and a lower amount of tumor necrosis in FGFR1-IIIb-expressing tumors.
|
17363592 |
2007 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
The mechanism by which bFGF rescued the bone lesion development was by promotion of tumor cell proliferation through the downstream mitogen-activated protein kinase (MAPK)-extracellular signal-regulated kinase (ERK)-cFos pathway after binding to the FGF receptor 1 (FGFR1).
|
26279296 |
2016 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Our findings are consistent with the results of the TCGA data set for the "squamous-like" subtype of bladder cancer (n = 85), which revealed reduced overall expression of FGFR1 and FGFR2 in tumors compared to normal tissue, while expression of FGFR3 remained high.
|
27669755 |
2016 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Extensive molecular and genetic work-up of the two tumors yielded divergent lesions in the two tumors: an activating KRAS mutation in the responsive tumor and an amplification of the fibroblast growth factor receptor-1 (FGFR1) locus in the treatment-refractory tumor.
|
22879364 |
2012 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
FGFR1 amplification was detected in 18.5% of patients whose tumors revealed a poor response to chemotherapy, and no patients whose tumors responded well to therapy harbored this genetic alteration.
|
24861215 |
2014 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
FGFR-1 and FGFR-3 were expressed in most well-differentiated tumor types.
|
15564323 |
2005 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
FGFR1 is a viable therapeutic target in a subset of MPMs, but FGFR TKI-responsive tumors will need to be selected by a biomarker distinct from increased FGFR1 gene copy number, possibly FGFR1 mRNA or protein levels.
|
24966347 |
2014 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
The level of FGFR1 amplification did not correlate with tumor stage, lymph node staging, or metastasis.
|
29351293 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Thus, the translational science presented here provides a strong rationale for investigation of AZD4547 as a therapeutic option for patients with squamous NSCLC tumors harboring amplification of FGFR1.
|
23082000 |
2012 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Aneuploid genomes were identified in 45% of adult compared with 17% of pediatric PA. Gains were non-random, favoring chromosomes 5, 7, 6 and 11 in order of frequency, and preferentially affecting non-cerebellar PA and tumors with BRAF V600E mutations and not with KIAA1549-BRAF fusions or FGFR1 mutations.
|
26378811 |
2015 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Furthermore, we discuss emerging therapeutic targets including novel oncogenic alterations (ROS1 rearrangements, FGFR1 amplifications, CMET amplifications, and others) and molecular features of the tumor microenvironment (including immune-checkpoint molecules such as CTLA4 and PD-1/PD-L1).
|
25287912 |
2014 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Both epidermal growth factor receptor (EGFR) and fibroblast growth factor receptor 1 (FGFR1) are overexpressed in the majority of human tumors, including ovarian cancer.
|
25919378 |
2015 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
In situ hybridization experiments were performed on tissue sections of normal breast and tumors with a high level of FGFR1 expression.
|
7927944 |
1994 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Neutralizing FGFR1-specific antibody abrogates the physiologic and chemoprotective effects of FGF-2/FGFR1beta signaling and inhibits tumor growth in mice xenotransplanted with human AML.
|
16598308 |
2006 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
An oncogenic fibroblast growth factor receptor 1 (FGFR1) mutation (N546K) was detected, and the FGFR1 locus frequently showed copy number gain (31.7%) in primary tumors.
|
26179511 |
2015 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
FGFR1 amplifications (n = 5) and chromosomal aberrations (trisomy, n = 38; high polysomy, n = 30) are associated with high-grade malignancy (P < 0.001), advanced tumour size (P = 0.026) and stage (P = 0.004), gender (P = 0.016) and age (P = 0.023).
|
26661925 |
2016 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
The 8p11 myeloproliferative syndrome (EMS) is an aggressive neoplasm associated with chromosomal translocations involving the fibroblast growth factor receptor 1 tyrosine kinase gene on chromosome 8p11-12.
|
21214407 |
2011 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Taken together, these results show the transforming activity of FGFR1 in mammary epithelial cells and identify RSK as a critical component of FGFR1 signaling in lobular carcinomas, thus implicating RSK as a candidate therapeutic target in FGFR1-expressing tumors.
|
19258500 |
2009 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The immunohistochemical results were as follows: the tumour cells were positive for FGF23 (nine of 12, 75%), FGFR1 (11 of 11, 100%), CD56 (12 of 14, 85.7%) and E26 oncogene homologue (ERG) (5 of 13, 38.4%).
|
28858396 |
2018 |